PRP and BMAC use materials collected from your own body, but they are prepared differently and are not equally suitable for every joint problem. This guide compares PRP with a BMAC injection, including how each treatment works, what current research shows and which factors may influence your decision.

How are BMAC and PRP different?

Platelet-rich plasma, or PRP, starts with a standard blood sample. The blood is processed to concentrate platelets and growth factors before the resulting preparation is injected into the painful or injured area.

PRP aims to support the body’s natural healing response and may help reduce pain and improve function. It is commonly considered for conditions such as knee osteoarthritis and persistent tendon injuries, although outcomes vary according to the diagnosis, preparation method and severity of the problem.

A BMAC injection involves collecting bone marrow, usually from the pelvic bone. The sample is then processed to produce bone marrow aspirate concentrate, which contains concentrated cells and proteins, including growth factors, cytokines and a relatively small number of mesenchymal stromal cells.

Because BMAC requires bone marrow aspiration, it is more involved than PRP. The procedure normally includes collection, processing and image-guided injection, while PRP only requires a blood draw before preparation and injection.

Which one works better?

There is no clear winner for every patient. The strongest direct comparison comes from research involving people with mild to moderate knee osteoarthritis, rather than every type of joint pain.

A randomised clinical trial found that both PRP and bone marrow concentrate improved patient-reported outcomes for knee osteoarthritis. At 12 months, neither treatment provided a clearly superior clinical benefit. Follow-up results at two years again found that BMAC was not superior to PRP.

Some smaller studies have reported greater improvements after BMAC. However, these studies have often involved fewer participants or different preparation methods, making it difficult to conclude that a BMAC injection consistently works better.

A 2024 meta-analysis comparing several injection therapies found that PRP significantly improved pain and function compared with placebo and ranked highly against BMAC, hyaluronic acid and corticosteroid injections. This does not prove that PRP is always best, but it supports the view that PRP currently has a broader and more established evidence base for knee osteoarthritis.

A 2025 review of BMAC found encouraging short- to medium-term results for some patients. However, it also noted inconsistent findings, differences between treatment protocols and limited evidence showing that BMAC produces better long-term outcomes than PRP.

When might each treatment be considered?

PRP may be considered first when a patient wants a less invasive biological treatment. It may be particularly relevant for mild to moderate knee osteoarthritis or certain tendon problems when physiotherapy, activity modification and other conservative treatments have not provided enough relief.

UK guidance remains cautious. NICE states that PRP for knee osteoarthritis raises no major safety concerns, but the quality of evidence supporting its effectiveness is limited. It therefore recommends using the procedure with special arrangements for clinical governance, informed consent and outcome monitoring.

A BMAC injection may be discussed when symptoms remain significant, the condition is more complex or previous treatments have not worked. Some specialists may also consider it when they believe the additional cellular and biological components found in bone marrow concentrate could be beneficial.

However, BMAC should not be treated as a guaranteed cartilage-regeneration procedure. Although it may help reduce pain, inflammation and stiffness for some people, it is not a cure, and there is not enough evidence to say that it will work for everyone.

The greater complexity also matters. Bone marrow collection may cause temporary soreness, and there are small risks of bleeding, infection, inflammation or no improvement. These factors should be balanced against the possible benefits before treatment.

Choosing the right option

Your diagnosis should guide the decision, not the treatment name. Joint pain can come from osteoarthritis, tendon damage, inflammatory conditions, injuries or problems outside the joint, and PRP or BMAC will not be appropriate for every cause.

You should also consider the severity of the condition, previous treatments, general health, recovery requirements and cost. PRP is usually simpler and less invasive, while BMAC requires a more complex collection and preparation process.

For many people with knee osteoarthritis, PRP may be the more reasonable first biological option because it has stronger supporting evidence and does not require bone marrow aspiration. A BMAC injection may still be considered for carefully selected patients, but current research does not show that it reliably produces better results.

Ultimately, neither treatment can guarantee pain relief or rebuild a severely damaged joint. A specialist assessment can confirm the cause of your symptoms, review your scans and explain whether PRP, BMAC or another treatment offers the most appropriate next step. Explore more information about regenerative joint treatments or contact The Regenesis Clinics to arrange an individual assessment.